Sebastien Mauel manages Ferring’s global program to implement serialisation capabilities at manufacturing sites in Europe, Asia and the USA. He also oversees the protection of Ferring products against counterfeiting and diversion.

Prior to joining Ferring, he worked at Serono and Merck Serono in Switzerland and Germany in a variety of Manufacturing, Logistics, Supply Chain, Serialisation and Product Security positions.

Sebastien holds a MS in Chemical Engineering from the Swiss Federal Institute of Technology and CIPM and CSCP certifications from APICS.

Ferring Pharmaceuticals is a research-driven, biopharmaceutical company devoted to identifying, developing and marketing innovative products in the fields of reproductive health, urology, gastroenterology, endocrinology and orthopaedics. The company's research activities and products are connected by a common focus of providing tailored treatments that work on the body's own terms, enabling doctors to combat numerous diseases and medical conditions. Ferring has its own manufacturing facilities in several European countries, in South America, Israel, India and China. It is also currently building new facilities in the USA. With the acquisition of Bio-Technology General in 2005, it has capabilities in recombinant biotechnology as well as more traditional pharmaceutical manufacturing. Ferring's marketing, medical services and sales teams, led by the corporate headquarters in Saint-Prex, Switzerland, operate from nearly 60 countries and employ over 6,000 people throughout the world, while treatments are available in 110 countries. This expansion has allowed Ferring to maintain a double-digit annual growth rate over the last two decades.